Ayvakit FDA Approval History
Last updated by Judith Stewart, BPharm on May 30, 2023.
FDA Approved: Yes (First approved January 9, 2020)
Brand name: Ayvakit
Generic name: avapritinib
Dosage form: Tablets
Company: Blueprint Medicines Corporation
Treatment for: Gastrointestinal Stromal Tumor, Systemic Mastocytosis
Ayvakit (avapritinib) is a tyrosine kinase inhibitor for use in the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, and indolent systemic mastocytosis.
- Ayvakit is indicated for:
- Gastrointestinal Stromal Tumor (GIST) - treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
- Advanced Systemic Mastocytosis (AdvSM) - treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).
- Indolent Systemic Mastocytosis (ISM) - treatment of adult patients with ISM.
- GIST is a sarcoma of the GI tract most often caused by mutations in KIT or PDGFRA that force protein kinases into an increasingly active state. Systemic mastocytosis (SM) is a rare hematologic disorder most often caused by the KIT D816V mutation. Ayvakit works in the treatment of GIST and SM by targeting KIT D816V, PDGFRA and PDGFRA D842 mutants.
- Ayvakit is administered orally, once daily.
- Warnings and precautions associated with Ayvakit include intracranial hemorrhage, cognitive adverse reactions, photosensitivity reactions, and fetal harm.
- Common adverse reactions in patients with GIST include edema, nausea, fatigue/asthenia, cognitive impairment, vomiting, decreased appetite, diarrhea, increased lacrimation, abdominal pain, constipation, rash, dizziness, and hair color changes.
Common adverse reactions in patients with AdvSM include edema, diarrhea, nausea, and fatigue/asthenia.
Common adverse reactions in patients with ISM include eye edema, dizziness, peripheral edema and flushing.
Development timeline for Ayvakit
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
